Acquisitions and License Agreements (Narrative) (Details) $ / shares in Units, $ in Millions								1 Months Ended	3 Months Ended								9 Months Ended	12 Months Ended			60 Months Ended
	Aug. 31, 2016 USD ($)	Feb. 01, 2016 USD ($)	Sep. 25, 2015 USD ($)	Apr. 16, 2015 USD ($)	Aug. 14, 2014 USD ($) $ / shares shares	Apr. 05, 2014 shares	Mar. 19, 2014 USD ($)	Jan. 31, 2014 USD ($)	Sep. 30, 2016 USD ($)	Jun. 24, 2016 USD ($)	Mar. 25, 2016 USD ($)	Dec. 25, 2015 USD ($)	Sep. 25, 2015 USD ($)	Jun. 26, 2015 USD ($)	Mar. 27, 2015 USD ($)	Dec. 26, 2014 USD ($)	Jun. 26, 2015 pharmacy_indications	Sep. 30, 2016 USD ($)	Sep. 25, 2015 USD ($)	Sep. 26, 2014 USD ($)	Sep. 27, 2013 USD ($)	Aug. 31, 2014 USD ($)	Jul. 28, 2014 USD ($)	Oct. 01, 2012 USD ($)
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired																		$ 245.4	$ 2,154.7	$ 2,793.8
Net sales									$ 887.2	$ 866.6	$ 815.8	$ 811.2	$ 778.8	$ 768.5	$ 709.5	$ 666.3		3,380.8	2,923.1	1,650.3
Non-cash impairment charges																		16.9	0.0	381.2
Nuvo
Business Acquisition [Line Items]
Non-cash impairment charges																				11.1
Stratatech [Member]
Business Acquisition [Line Items]
Contingent consideration	$ 54.9
Business Combination, Consideration Transferred, Other	76.0
Total consideration	130.9
Total Debt	1.0
Contingent consideration, potential maximum	$ 121.0
Hemostasis Products
Business Acquisition [Line Items]
Contingent consideration		$ 52.0
Business Combination, Consideration Transferred, Other		173.5
Total consideration		225.5
Total Debt		0.0
Contingent consideration, potential maximum		395.0
Therakos
Business Acquisition [Line Items]
Contingent consideration			$ 0.0										0.0						0.0
Business Combination, Consideration Transferred, Other			1,300.0
Total consideration			1,019.1
Cash used to acquire business			1,000.0
Total Debt			344.8										344.8						344.8
Net sales																		207.6	0.0	0.0
Ikaria
Business Acquisition [Line Items]
Contingent consideration				$ 0.0
Business Combination, Consideration Transferred, Other				2,300.0
Total consideration				1,253.6
Cash used to acquire business				1,200.0
Total Debt				1,121.0
Long Term Debt Assumed				1,100.0
Net sales																		491.5	191.9	0.0
Questcor Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Contingent consideration					$ 0.0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability									123.4									123.4				$ 195.4
Total consideration					$ 5,915.3
Amount of Cash Shareholders Receive, Per Share of Acquiree | $ / shares					$ 30.00
Amount of company shares shareholders will receive, per share | shares						0.897
Issuance of common stock to acquire business | shares					57,000,000
Total Debt					$ 0.0
Contingent consideration, potential maximum									165.0									165.0
Net sales																		1,218.4	1,125.9	129.2
Cadence Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Contingent consideration							$ 0.0
Total consideration							1,329.2
Total Debt							30.0
Net sales																		284.3	263.0	124.4
CNS Therapeutics, Inc.
Business Acquisition [Line Items]
Contingent consideration																								$ 6.9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability									$ 0.9									0.9
Contingent consideration, potential maximum																								$ 9.0
Raplixa [Member] | Hemostasis Products
Business Acquisition [Line Items]
Contingent consideration		52.0
PreveLeak [Member] | Hemostasis Products
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability		$ 10.6
Acthar | Questcor Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Number of indications that are approved for treatment | pharmacy_indications																	19
Bristol-Myers Squibb | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																		25.0
Royalties paid																		46.3	43.9	13.2
Ofirmev | Cadence Pharmaceuticals, Inc. | Licensing Agreements
Business Acquisition [Line Items]
Milestone Payments																			10.0
Exalgo | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																			73.0
Royalties paid																		0.9	3.2	22.0
Milestone Payments																					$ 65.0
Depomed | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																		$ 64.0
Milestone Payments																				$ 10.0	22.0
Pennsaid | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																			120.0
Milestone Payments																					15.0
Finite-Lived Intangible Assets | Exalgo | Licensing Agreements
Business Acquisition [Line Items]
Milestone Payments																					$ 55.0
Royalty rights | Exalgo
Business Acquisition [Line Items]
Finite-lived intangible assets acquired								$ 7.2
Debentures | Therakos
Business Acquisition [Line Items]
Long term debt			750.0
Debentures | Ikaria
Business Acquisition [Line Items]
Long term debt				1,400.0
Debentures | Questcor Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Long term debt					900.0
Revolving Credit Facility | Therakos
Business Acquisition [Line Items]
Borrowings, outstanding			$ 500.0										$ 500.0						$ 500.0
Revolving Credit Facility | Ikaria
Business Acquisition [Line Items]
Borrowings, outstanding				$ 240.0
Secured Debt | Questcor Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Long term debt					700.0
Variable rate receivable securitization | Questcor Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Long term debt					$ 150.0
Variable rate receivable securitization | Secured Debt
Business Acquisition [Line Items]
Debt instrument, face amount																							$ 160.0
Interest rate during period																		1.33%
Revolving Credit Facility | Revolving Credit Facility
Business Acquisition [Line Items]
Interest rate during period																		2.60%
Term loan due March 2021 | Secured Debt
Business Acquisition [Line Items]
Debt instrument, face amount							1,300.0
Interest rate during period																		3.43%
Specialty Pharmaceuticals | Cadence Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Total consideration							$ 1,300.0